临床常用氟喹诺酮类药物治疗下呼吸道感染的成本－效果分析

摘要

目的：探讨临床常用氟喹诺酮类药物治疗下呼吸道感染的药物经济学效果。方法：选择解放军第153中心医院（以下简称“我院”）门诊下呼吸道感染患者120例，随机分为3组，分别给予左氧氟沙星（左氧氟沙星组）1个疗程（5 d）、莫西沙星（莫西沙星组）1个疗程（7 d）、加替沙星（加替沙星组）1个疗程（7 d），应用药物经济学方法进行成本－效果分析。结果：3组成本分别为287．0、315．0、460．6元；有效率分别为100％、80％、95％；成本－效果比分别为2．87、3．94、4．85；莫西沙星组增量成本－效果比为－1．40，加替沙星组增量成本－效果比为－34．72。结论：左氧氟沙星治疗下呼吸道感染疗效好、成本低，且不良反应最少。%OBJECTIVE:To evaluate the pharmacoeconomic efficacy of clinical commonly used drugs in the treatment of lower respiratory tract bacterial infection.METHODS:120 patients with lower respiratory tract infection in No.153 Central Hospital of the Chinese People's Liberation Army were randomly assigned to receive levofloxacin for 5 days ( group A) , moxifloxacin for 7 days ( group B) or gatifloxacin for 7 days ( group C) .A cost-effectiveness analysis was performed on three groups.RESULTS: The costs in 3 groups were 287 yuan, 315 yuan and 460.6 yuan, respectively;with effective rates of 100%, 80% and 95% ( C/E) , and cost-effectiveness ratios of 2.87, 3.94 and 4.85, respectively.The incremental cost-effectiveness ratio was -1.4 for group B, as compared with -34.72 for group C.CONCLUSIONS:In the treatment of lower respiratory tract infection, Levofloxacin is effective with low cost and the least adverse reaction.